SCHEMBL1012134

SCHEMBL1012134

CCOC(=O)c1cnc(N2CCOCC2)nc1C(C)(C)C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.58
ALOX15 P16050 2/20 0.56
CNR2 P34972 1/20 0.56
HSD11B1 P28845 1/20 0.52
TP53 P04637 2/20 0.50
MAPK1 P28482 2/20 0.50
HSD17B10 Q99714 2/20 0.50
USP2 O75604 1/20 0.50
RECQL P46063 1/20 0.50
PKM P14618 1/20 0.48
L3MBTL1 Q9Y468 3/20 0.47
ADORA3 P0DMS8 1/20 0.47
ADORA2A P29274 1/20 0.47
LMNA P02545 3/20 0.47
ALDH1A1 P00352 2/20 0.47
PIK3CA P42336 1/20 0.46
MAPT P10636 5/20 0.46
GAA P10253 3/20 0.46
POLB P06746 3/20 0.46
DYRK1A Q13627 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL242697 0.84 KDM4E (0.61) KDM4EALOX15CNR2TP53MAPK1
SCHEMBL244184 0.83 KDM4E (0.66) KDM4EALOX15TP53MAPK1HSD17B10
SCHEMBL244096 0.83 KDM4E (0.60) KDM4EALOX15CNR2TP53MAPK1
SCHEMBL1015076 0.83 HSD11B1 (0.57) KDM4ECNR2HSD11B1MAPK1HSD17B10
SCHEMBL13696639 0.82 KDM4E (0.59) KDM4EALOX15CNR2TP53MAPK1
SCHEMBL12929380 0.81 KDM4E (0.61) KDM4EALOX15CNR2TP53MAPK1
SCHEMBL14590419 0.81 MAPT (0.59) KDM4EALOX15CNR2TP53MAPK1
SCHEMBL1014816 0.81 KDM4E (0.57) KDM4EALOX15CNR2HSD11B1TP53
SCHEMBL573492 0.79 ALOX15 (0.61) KDM4EALOX15TP53MAPK1HSD17B10
SCHEMBL1015952 0.79 HSD11B1 (0.57) KDM4EALOX15CNR2HSD11B1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2271629-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 AstraZeneca AB (SE) 2011-01-12 EP disclosed
WO-2009130496-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 ASTRAZENECA AB (SE) 2009-10-29 WO disclosed
WO-2009130496-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 ASTRAZENECA AB (SE) 2009-10-29 WO disclosed
US-20090264401-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 ASTRAZENECA AB (SE) 2009-10-22 US disclosed
US-20090264401-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 ASTRAZENECA AB (SE) 2009-10-22 US disclosed
US-20090264401-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 ASTRAZENECA AB (SE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264401-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 CYP2S1, HSD11B1, HSD3B1 KDM4E 1727/4885ALOX15 242/4885CNR2 576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.